Adiponectin
Evidence: CNeuroendocrine / Appetite-Energy Balance Signaling
Evidence Snapshot
What this grade covers
Large, well-replicated human OBSERVATIONAL evidence base (Arita 1999, Hotta 2000) directly linking lower circulating adiponectin to obesity and type 2 diabetes, plus a human genetic locus (Ling 2009) and HMW-form-specific observational data (Pajvani 2007). Zero human administration/intervention evidence exists. ASSOCIATION_DOES_NOT_ESTABLISH_CAUSATION is a mandatory, non-waivable framing rule for this entire page. Overall page grade: C.
Regulatory Context
Native Adiponectin is an endogenous human hormone and is not itself an FDA-approved drug product.
In Plain English
A quick, research-focused overview. It does not replace, and cannot outrank, the detailed evidence below.
What is it?
A hormone made by fat cells (adipocytes), discovered in 1995 and originally named Acrp30.
Why are researchers interested in it?
Studied for its strong, replicated inverse association with obesity, insulin resistance, and type 2 diabetes.
What does the evidence look like?
Large human observational and genetic evidence base; zero human intervention/administration studies.
Biggest things to know
Lower blood adiponectin is associated with obesity and type 2 diabetes; the high-molecular-weight (HMW) form specifically is selectively downregulated in hyperinsulinemia and T2DM.
What don't we know yet?
Whether raising adiponectin in humans would improve obesity or diabetes outcomes -- no intervention study has tested this.
Research Takeaway
Adiponectin (originally described as Acrp30) is a 30 kDa protein produced exclusively by adipocytes, structurally similar to complement factor C1q.
Evidence boundary: Identity/discovery only.
See all 4 evidence claims →Quick Summary
Adiponectin is an adipocyte-derived hormone, discovered in 1995, whose circulating levels are consistently lower -- not higher -- in people with obesity and type 2 diabetes. All human evidence is observational; no study has raised adiponectin in humans to test whether it changes outcomes.
Mechanism & Research Overview
Adiponectin is an adipocyte-derived hormone, discovered in 1995, whose circulating levels are consistently lower -- not higher -- in people with obesity and type 2 diabetes. All human evidence is observational; no study has raised adiponectin in humans to test whether it changes outcomes.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Adiponectin (originally described as Acrp30) is a 30 kDa protein produced exclusively by adipocytes, structurally similar to complement factor C1q.
Does not establish
Evidence boundary: Identity/discovery only.
Sources: A novel serum protein similar to C1q, produced exclusively in adipocytes
Supported
Circulating adiponectin is paradoxically lower, not higher, in individuals with obesity compared to non-obese individuals.
Does not establish
Evidence boundary: Cross-sectional association only, not causal; does not establish that raising adiponectin would change obesity risk or outcomes -- see risk-adipo-01 (ASSOCIATION_DOES_NOT_ESTABLISH_CAUSATION).
Sources: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity
Supported
Plasma adiponectin is lower in type 2 diabetic patients than non-diabetic subjects (6.6 vs. 7.9 ug/mL men; 7.6 vs. 11.7 ug/mL women, both p<0.01).
Does not establish
Evidence boundary: Cross-sectional association only, not causal; does not establish that raising adiponectin would treat or prevent type 2 diabetes -- see risk-adipo-01 (ASSOCIATION_DOES_NOT_ESTABLISH_CAUSATION).
Sources: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients
Supported
The high-molecular-weight (HMW) form of adiponectin is selectively downregulated in hyperinsulinemia and type 2 diabetes, distinct from lower-molecular-weight forms.
Does not establish
Evidence boundary: Any HMW-specific statement must cite this source specifically, not the general total-adiponectin claims above.
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
HMW-specific findings (Pajvani 2007) must not be silently applied to total/other adiponectin forms or vice versa.Safety Consideration
All human evidence for adiponectin is observational/genetic; no study has raised adiponectin in humans and measured a clinical outcome. Lower adiponectin being ASSOCIATED with obesity/T2DM does not mean raising it would treat either condition.
Research Areas Being Studied
Research areas discussed on this page reflect the Neuroendocrine / Appetite-Energy Balance Signaling category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- Genome-wide linkage and association analyses to identify genes influencing adiponectin levels: the GEMS Study (2009):
- Selective Downregulation of the High-Molecular Weight Form of Adiponectin in Hyperinsulinemia and in Type 2 Diabetes (2007):
- Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients (2000):
- Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity (1999):
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Genome-wide linkage and association analyses to identify genes influencing adiponectin levels: the GEMS Study | 2009 | GEMS Study cohorts | Genome-wide linkage and association scan identifies the ADIPOQ locus as the major genetic determinant of circulating adiponectin levels in humans. | ||
| Selective Downregulation of the High-Molecular Weight Form of Adiponectin in Hyperinsulinemia and in Type 2 Diabetes | 2007 | Human cohorts, hyperinsulinemia / T2DM vs non-diabetic | The high-molecular-weight (HMW) form of adiponectin is selectively downregulated in hyperinsulinemia and type 2 diabetes, distinct from lower-molecular-weight forms. | ||
| Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients | 2000 | Type 2 diabetic vs non-diabetic subjects | Plasma adiponectin lower in T2DM patients than non-diabetic subjects (6.6 vs 7.9 ug/mL men; 7.6 vs 11.7 ug/mL women, both p<0.01). | ||
| Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity | 1999 | Human cross-sectional cohort | Circulating adiponectin is paradoxically lower, not higher, in individuals with obesity compared to non-obese individuals. |
Animal / Cell / Preclinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| A novel serum protein similar to C1q, produced exclusively in adipocytes | 1995 | 3T3-L1 adipocyte cell line | Discovery of Acrp30 (now known as adiponectin): a 30 kDa protein produced exclusively by adipocytes, structurally similar to complement factor C1q, induced >100-fold during adipocyte differentiation. |
Regulatory Documents & Official Trial Registries
No Regulatory Documents & Official Trial Registries Listed Yet
This section will be updated as sources are added.
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Association with obesity and diabetes does not prove that raising adiponectin would treat either condition.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated 2026-08-28.
Follow research updates for Adiponectin
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.